

Shahrul Mt-Isa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5824101/publications.pdf>

Version: 2024-02-01

33
papers

2,836
citations

430874

18
h-index

414414

32
g-index

33
all docs

33
docs citations

33
times ranked

5590
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. <i>Gut</i> , 2015, 64, 1744-1754.	12.1	950
2	Genetic Loci Associated With C-Reactive Protein Levels and Risk of Coronary Heart Disease. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 37.	7.4	544
3	Variations in Primary Open-Angle Glaucoma Prevalence by Age, Gender, and Race: A Bayesian Meta-Analysis. , 2006, 47, 4254.		394
4	Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation. <i>Thorax</i> , 2013, 68, 532-539.	5.6	121
5	Emergency department treatments and physiotherapy for acute whiplash: a pragmatic, two-step, randomised controlled trial. <i>Lancet</i> , The, 2013, 381, 546-556.	13.7	102
6	Advice to use topical or oral ibuprofen for chronic knee pain in older people: randomised controlled trial and patient preference study. <i>BMJ: British Medical Journal</i> , 2008, 336, 138-142.	2.3	99
7	Balancing benefit and risk of medicines: a systematic review and classification of available methodologies. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 667-678.	1.9	92
8	Where errors occur in the preparation and administration of intravenous medicines: a systematic review and Bayesian analysis. <i>Quality and Safety in Health Care</i> , 2010, 19, 341-345.	2.5	89
9	Recommendations for benefitâ€“risk assessment methodologies and visual representations. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 251-262.	1.9	51
10	A case study using the PrOACTâ€“URL and BRAT frameworks for structured benefit risk assessment. <i>Biometrical Journal</i> , 2016, 58, 8-27.	1.0	34
11	Does a monetary incentive improve the response to a postal questionnaire in a randomised controlled trial? The MINT incentive study. <i>Trials</i> , 2009, 10, 44.	1.6	30
12	Pharmacokinetics, adverse effects and tolerability of a novel analogue of human pancreatic polypeptide, PP 1420. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 232-239.	2.4	30
13	Managing Injuries of the Neck Trial (MINT): design of a randomised controlled trial of treatments for whiplash associated disorders. <i>BMC Musculoskeletal Disorders</i> , 2007, 8, 7.	1.9	28
14	Managing Injuries of the Neck Trial (MINT): a randomised controlled trial of treatments for whiplash injuries. <i>Health Technology Assessment</i> , 2012, 16, iii-iv, 1-141.	2.8	28
15	Structured Benefitâ€“risk assessment: a review of key publications and initiatives on frameworks and methodologies. <i>Pharmaceutical Statistics</i> , 2016, 15, 324-332.	1.3	27
16	Direct-to-Patient Research: Piloting a New Approach to Understanding Drug Safety During Pregnancy. <i>JMIR Public Health and Surveillance</i> , 2015, 1, e22.	2.6	26
17	Literature review of visual representation of the results of benefitâ€“risk assessments of medicinal products. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 238-250.	1.9	22
18	A Bayesian approach to probabilistic sensitivity analysis in structured benefitâ€“risk assessment. <i>Biometrical Journal</i> , 2016, 58, 28-42.	1.0	21

#	ARTICLE	IF	CITATIONS
19	Cost-effectiveness of advising the use of topical or oral ibuprofen for knee pain; the TOIB study [ISRCTN: 79353052]. <i>Rheumatology</i> , 2008, 47, 1077-1081.	1.9	18
20	Cumulative flying time and risk of venous thromboembolism. <i>British Journal of Haematology</i> , 2011, 155, 613-619.	2.5	17
21	Benefit-risk assessment in a post-market setting: a case study integrating real-life experience into benefit-risk methodology. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 974-983.	1.9	17
22	Lack of effect of influenza immunisation on anticoagulant control in patients on long-term warfarin. <i>Pharmacoepidemiology and Drug Safety</i> , 2007, 16, 786-789.	1.9	16
23	Modelling Cognitive Decline in the Hypertension in the Very Elderly Trial [HYVET] and Proposed Risk Tables for Population Use. <i>PLoS ONE</i> , 2010, 5, e11775.	2.5	15
24	Balancing the Interests of Patient Data Protection and Medication Safety Monitoring in a Public-Private Partnership. <i>JMIR Medical Informatics</i> , 2015, 3, e18.	2.6	12
25	Republished paper: Where errors occur in the preparation and administration of intravenous medicines: a systematic review and Bayesian analysis. <i>Postgraduate Medical Journal</i> , 2010, 86, 734-738.	1.8	11
26	Challenges and methodology in the incorporation of biomarkers in cancer clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 110, 49-61.	4.4	8
27	Comparison of electronic self-reported prescription medication use during pregnancy with the national prescription register in Denmark. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 328-336.	1.9	8
28	Impact of Letermovir Use for Cytomegalovirus Prophylaxis on Re-Hospitalization Following Allogeneic Hematopoietic Stem Cell Transplantation: An Analysis of a Phase III Randomized Clinical Trial. <i>PharmacoEconomics - Open</i> , 2021, 5, 469-473.	1.8	8
29	Weighing benefit-risk of medicines: concepts and approaches. <i>Drug Discovery Today: Technologies</i> , 2011, 8, e29-e35.	4.0	6
30	An International Study of the Ability and Cost-Effectiveness of Advertising Methods to Facilitate Study Participant Self-Enrolment Into a Pilot Pharmacovigilance Study During Early Pregnancy. <i>JMIR Public Health and Surveillance</i> , 2016, 2, e13.	2.6	5
31	Periodic benefit-risk assessment using Bayesian stochastic multi-criteria acceptability analysis. <i>Contemporary Clinical Trials</i> , 2018, 67, 100-108.	1.8	4
32	Bayesian credible subgroup identification for treatment effectiveness in time-to-event data. <i>PLoS ONE</i> , 2020, 15, e0229336.	2.5	2
33	A Bayesian approach for individual-level drug benefit-risk assessment. <i>Statistics in Medicine</i> , 2019, 38, 3040-3052.	1.6	1